GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Gelteq Limited
Gelteq's value as a pharmaceutical company is determined by its technology platform and development pipeline. Its potential share price will depend on clinical trial success, partnerships, and the commercial potential of its products.
Share prices of companies in the market segment - Specialized pharma
Gelteq is an Australian company that develops and manufactures innovative drug delivery systems in the form of gels and films for the pharmaceutical and cosmetic industries. We have classified it as a "Specialty Pharmaceutical" company. The chart below shows how the market values companies with new delivery technologies.
Broad Market Index - GURU.Markets
Gelteq is an Australian pharmaceutical company developing innovative gel formulations for oral drug delivery. As a participant in this sector, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it with the company's stock to assess the industry's prospects.
Change in the price of a company, segment, and market as a whole per day
GELS - Daily change in the company's share price Gelteq Limited
For Gelteq Limited, a drug delivery company, daily volatility reflects sensitivity to news about partnerships with pharmaceutical companies. This metric is an important element in formulas assessing the risks and potential in this niche.
Daily change in the price of a set of shares in a market segment - Specialized pharma
The specialty pharmaceutical sector in which Gelteq Limited operates is highly dynamic. This chart reflects the industry's average volatility. It serves as a benchmark for assessing Gelteq's drug development business's sensitivity to general trends and clinical trial news.
Daily change in the price of a broad market stock, index - GURU.Markets
Gelteq is a pharmaceutical company developing new drugs. Its shares, like many in the sector, are volatile and react to news about clinical trials. These scientifically driven movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Gelteq Limited
Gelteq Limited's annual performance is a story of developing innovative drug delivery systems. Its 12-month market cap depends on progress in developing its edible gel platforms, which could replace tablets and capsules. Successful partnerships with pharmaceutical companies will serve as fundamental validation of its technology.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Gelteq, as a private pharmaceutical company, likely specializes in developing innovative drug delivery systems. Its growth depends on successful clinical trials and partnerships. Its valuation dynamics will reflect investors' faith in its science, potentially outperforming the sector if successful.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Gelteq, with its edible drug delivery technology, is an innovative company whose success depends on partnerships. Its performance relative to the market reflects not its own sales, but rather investors' faith in the adoption of its technology by major pharmaceutical companies. Each new contract could trigger explosive share price growth.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Gelteq Limited
Gelteq is a pharmaceutical company developing gel-based medications. Its monthly performance is driven by progress in its clinical programs and partnerships. News of trial results for its innovative drug delivery system is the main driver of its valuation.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
Gelteq is an Australian pharmaceutical company specializing in the development and production of oral gel dosage forms (Gelteq). This technology improves the delivery and absorption of active ingredients. The graph below illustrates the dynamics of the pharmaceutical sector, where innovations in drug delivery methods play a significant role.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Gelteq is an Australian company developing innovative gel-based drug delivery systems. It's a pharma venture capital story. Its stock will move based on news of partnerships and development successes, rather than general market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Gelteq Limited
Gelteq is an Australian company developing new drug delivery systems. As an early-stage pharmaceutical company, its weekly stock price will be highly sensitive to news about partnerships and research results.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Gelteq is a pharmaceutical company with a unique drug delivery technology. Use this chart to analyze: are the company's weekly stock movements driven by internal news (such as partnerships) or simply following the overall sentiment in the biotech sector?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Gelteq Limited is a pharmaceutical company whose shares follow the rhythm of news about clinical trials and partnerships. The chart clearly shows how its weekly performance is detached from the broader market, moving along its own unique trajectory.
Market capitalization of the company, segment and market as a whole
GELS - Market capitalization of the company Gelteq Limited
Gelteq Limited's market cap is a bet on a new drug delivery technology. The stock price of this company, which develops edible gel forms for medications, reflects investors' belief that its technology can replace traditional tablets and capsules. It's a venture capital story in the pharmaceutical world.
GELS - Share of the company's market capitalization Gelteq Limited within the market segment - Specialized pharma
Gelteq is a specialized pharmaceutical company developing innovative drug delivery systems, particularly in gel form. Its market capitalization in its segment reflects the potential of its technology to improve the absorption and ease of administration of existing medications. The company's clout reflects its bet on the market acceptance of its developments by major pharmaceutical companies.
Market capitalization of the market segment - Specialized pharma
Gelteq develops new drug delivery systems. How big is this industry? The chart below shows the overall market capitalization of the specialized pharmaceutical sector. Its growth reflects the constant search for innovations that can make medications more effective, safer, and more convenient for patients.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Gelteq chart is a visualization of a bet on a new drug delivery technology. The market cap of the company, which develops edible gel forms for oral administration, reflects investors' faith in the potential of this innovation. It's a diagram showing how something already familiar can be improved.
Book value capitalization of the company, segment and market as a whole
GELS - Book value capitalization of the company Gelteq Limited
For Gelteq, which is developing an oral drug delivery platform, book value is its physical foundation: laboratories, production facilities for creating gel capsules, and financial reserves. The chart below shows how the company built this physical foundation for its pharmaceutical innovations.
GELS - Share of the company's book capitalization Gelteq Limited within the market segment - Specialized pharma
Gelteq Limited develops innovative drug delivery systems. Its tangible assets include laboratories and pilot production lines for creating edible gel formulations. These facilities are the physical foundation for a new era in pharmaceuticals. The chart shows the share of this cutting-edge R&D infrastructure the company controls.
Market segment balance sheet capitalization - Specialized pharma
Gelteq is a pharmaceutical company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Gelteq focuses on developing new drug delivery systems, and its capital lies in its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Gelteq's assets are not drugs, but laboratories and a pilot plant for developing its oral drug delivery technology in gel form (gel tablets). Its book value reflects its scientific potential aimed at improving the consumer properties of medications.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Gelteq Limited
Gelteq develops edible gel capsules for drug and nutraceutical delivery. The company has no tangible assets. Its market capitalization is based on its patented technology. The chart shows how investors assess its potential to offer a more convenient and effective alternative to traditional tablets and capsules.
Market to book capitalization ratio in a market segment - Specialized pharma
Gelteq develops and manufactures innovative gel-based drug delivery systems. Its value is determined by its patents and partnerships with pharmaceutical companies. The chart shows the market premium for its unique technology compared to the book value of its laboratories.
Market to book capitalization ratio for the market as a whole
Gelteq develops new drug delivery systems. Patents and research are its only real asset in the eyes of investors eager to partner with big pharma. This chart shows how speculative expectations in biotech create market value that can be hundreds of times greater than the book value of its assets.
Debts of the company, segment and market as a whole
GELS - Company debts Gelteq Limited
Gelteq is a company that may specialize in developing drug delivery systems, such as gels. Pharmaceutical innovation requires significant investment in research and clinical trials. This chart shows how the company raises capital to finance its scientific platform and advance its developments toward commercialization.
Market segment debts - Specialized pharma
Gelteq specializes in the development and production of oral gel-based dosage forms. This innovative approach requires investment in R&D and pharmaceutical-grade manufacturing capabilities. This chart shows how the company funds its development and production scale-up.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Gelteq Limited
Gelteq Limited specializes in pharmaceutical development. This chart shows its dependence on external financing. For a company working on new drug delivery systems but not yet achieving mass sales, debt is a significant risk. Its financial future depends on successful partnerships with major pharmaceutical companies and regulatory approvals.
Market segment debt to market segment book capitalization - Specialized pharma
Gelteq Limited specializes in developing innovative drug delivery systems, possibly gel-based. This is a niche area in the pharmaceutical industry. The chart shows the overall debt burden in the pharmaceutical industry, providing context for assessing how the company finances its unique R&D programs compared to more traditional pharmaceutical companies.
Debt to book value of all companies in the market
Gelteq Limited is developing an innovative gel-based drug delivery system. Being in the development stage, the company has no commercial products and relies on investment. This chart clearly demonstrates that the debt market is closed to such research and development projects, and their funding is a venture bet on the success of the future technology.
P/E of the company, segment and market as a whole
P/E - Gelteq Limited
This chart for Gelteq, a company developing drug delivery systems, reflects the potential of its technology. The price-to-earnings (P/E) (when available) will be based on the success of its partnerships with major pharmaceutical companies. This is a valuation not of the drug itself, but of the innovative delivery system.
P/E of the market segment - Specialized pharma
Gelteq is a pharmaceutical company specializing in the development and production of oral gel dosage forms. This technology improves the delivery and absorption of active ingredients. This chart shows the average rating for the sector, helping to understand how the market views this innovative drug delivery technology.
P/E of the market as a whole
Gelteq is a company specializing in the development and production of oral gel-based dosage forms. Its valuation is a bet on the success of its drug delivery technology among pharmaceutical companies. It is not tied to general economic cycles, but depends on partnerships and the success of its unique technology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Gelteq Limited
Gelteq is an Australian pharmaceutical company developing new drug delivery methods, particularly through oral gel formulations. This chart reflects investor expectations for its platform and partnerships with other pharmaceutical companies. The valuation is based on the technology's potential to improve existing drugs, not on current sales.
%20P%2FE%20Gelteq%20Limited&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Gelteq-Limited&v=1772635368562 "Chart of the company's future (projected) P/E Gelteq Limited")
Future (projected) P/E of the market segment - Specialized pharma
Gelteq is a specialty pharmaceutical company developing new drug delivery methods. Its valuation relative to other biotech and pharmaceutical companies reflects investor sentiment on the potential of its technology platform. This demonstrates the market's confidence in its ability to improve existing drugs and create new products.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772635368576 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Gelteq is likely a pharmaceutical company specializing in the development of gel-based medications. This could be a drug delivery system or specific products. This chart shows the overall risk appetite of investors. For companies with innovative but unproven technologies, a positive market environment is important to attract attention and capital.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772635368598 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Gelteq Limited
Gelteq is an Australian company developing innovative drug delivery systems in the form of gels and films for oral administration. The financial indicators shown in the graph reflect its status in the research and development phase. Future success depends on partnerships with pharmaceutical companies and the commercialization of its technology.
Profit of companies in the market segment - Specialized pharma
Gelteq Limited specializes in the development and production of gel formulations for drug delivery. This chart reflects overall profitability in the specialty pharmaceutical sector. It helps assess the demand for innovative drug delivery systems that can improve the efficacy and convenience of therapy for patients.
Overall market profit
Gelteq is a company specializing in the development and production of gel formulations for drug delivery. Its business depends on contracts with pharmaceutical companies. GELS's success is determined by its technology platform and ability to solve customer problems, rather than by general economic cycles, as illustrated by this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Gelteq Limited
Gelteq Limited specializes in the development and production of pharmaceutical gel products. The company's future profitability depends on the success of its developments and partnerships with other pharmaceutical companies. This chart shows how analysts assess the potential of its unique drug delivery technology and the commercial prospects of its products.
%20profit%20of%20the%20company%20Gelteq%20Limited&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Gelteq-Limited&v=1772635368705 "Graph of future (projected) profit of the company Gelteq Limited")
Future (predicted) profit of companies in the market segment - Specialized pharma
Gelteq is a specialized pharmaceutical company that is likely developing gel-based dosage forms to improve the delivery of active ingredients. This chart shows forecasts for the pharmaceutical sector. It helps assess how innovations in drug delivery methods can create new niches and impact overall industry profitability by improving the effectiveness of existing drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772635368750 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
For Gelteq, a company operating in the specialty pharmaceuticals niche, this schedule is important for access to funding. A positive market outlook facilitates attracting investment for research and development of new drug delivery systems, while a negative trend complicates this process.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772635368776 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Gelteq Limited
Gelteq develops new drug delivery systems. With minimal or no commercial revenue, this metric reflects investors' faith in its technology. It's an assessment of the platform's potential, not current cash flows.
P/S market segment - Specialized pharma
Gelteq is a pharmaceutical company specializing in the development and production of gel-based dosage forms. This chart shows the average valuation in the specialty pharmaceuticals sector. It helps understand how investors view Gelteq's unique drug delivery technology and its potential to improve existing drugs and create new ones.
P/S of the market as a whole
Gelteq Limited specializes in the development and production of gel formulations for drug delivery. This is a niche technology that can improve the effectiveness of existing drugs. Future revenue depends on partnerships with major pharmaceutical companies. This chart provides context for valuing a company with a highly specialized but potentially valuable technology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Gelteq Limited
Gelteq Limited specializes in the development and production of oral gel dosage forms. Future revenue depends on partnerships with pharmaceutical companies to implement its technology. The chart reflects the market's assessment of the potential of this innovative drug delivery system.
%20P%2FS%20Gelteq%20Limited&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Gelteq-Limited&v=1772635368949 "The graph of the company's future (projected) P/S Gelteq Limited")
Future (projected) P/S of the market segment - Specialized pharma
Gelteq is a company likely developing pharmaceuticals or medical devices based on gel technology. This could include drug delivery systems or wound care products. This chart shows how investors assess the commercial potential of its specialized technology compared to other pharmaceutical companies.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772635368989 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
This reflects investors' faith in innovative drug delivery methods. For Gelteq, a company developing oral gel formulations for medications, this is an indicator of the market's appetite for new technologies. Investor optimism helps fund research that could make medication administration more convenient and effective for patients.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772635369042 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Gelteq Limited
Gelteq is an Australian company specializing in the development and production of innovative drug delivery systems, particularly in the form of gels and chewable lozenges. This graph will reflect revenue from partnerships with pharmaceutical companies and, potentially, from sales of its own products. Growth will reflect demand for more patient-friendly drug delivery systems.
Sales of companies in the market segment - Specialized pharma
Gelteq is a company specializing in the development and production of oral gel formulations for drug delivery. This chart shows the dynamics in the specialty pharmaceutical sector. Gelteq's innovative technology can replace tablets and capsules, improving absorption and ease of administration, which is an important niche in the development of new dosage forms.
Overall market sales
Gelteq Limited specializes in the development and production of gel formulations for drug delivery. Its success depends on partnerships with pharmaceutical companies. The overall economic situation, shown in this chart, influences R&D budgets in the pharmaceutical industry and their interest in innovative active substance delivery systems.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Gelteq Limited
Gelteq specializes in the development and production of oral gel-based dosage forms that improve drug delivery and absorption. Its future revenue depends on partnerships with pharmaceutical companies. This chart reflects analysts' assessments of the potential of gel delivery technology and the signing of new licensing agreements.
%20sales%20of%20the%20company%20Gelteq%20Limited&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Gelteq-Limited&v=1772635369285 "Schedule of future (projected) sales of the company Gelteq Limited")
Future (projected) sales of companies in the market segment - Specialized pharma
Gelteq Limited specializes in developing innovative drug delivery systems. This chart shows expectations for the entire specialty pharmaceutical sector. It helps understand the potential analysts see in new technologies that improve the efficacy and ease of administration of medications.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772635369313 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Gelteq Limited specializes in the development and production of innovative drug delivery systems, particularly in gel and film form. Its success depends on partnerships with pharmaceutical companies. The overall economic situation, reflected in this chart, influences pharmaceutical companies' R&D budgets and their willingness to invest in new drug delivery technologies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772635369357 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Gelteq Limited
Gelteq specializes in the development and production of pharmaceutical gels. This chart illustrates the profitability of this niche drug delivery technology. The company's profitability depends on successful partnerships with major pharmaceutical companies, which use its technology to improve their products and pay royalties.
Market segment marginality - Specialized pharma
Gelteq Limited specializes in the development and production of gel-based medications, which improve their delivery to the body. For a pharmaceutical company, this technology can be the key to high profitability. This chart shows the average profitability in the pharmaceutical sector, helping to assess the potential financial success of Gelteq's innovative approach.
Market marginality as a whole
Gelteq is a company developing innovative gel-based drug delivery systems. This overall market profitability chart is not directly relevant to the company. Its potential lies in its ability to offer pharmaceutical companies more convenient and effective drug delivery methods, which could create new treatment standards and ensure high margins.
Employees in the company, segment and market as a whole
Number of employees in the company Gelteq Limited
Gelteq is developing an innovative platform for oral drug delivery in gel form. This graph shows a small team of scientists and developers. The staff size is typical for an early-stage company focused on patenting and proving the effectiveness of its technology.
Share of the company's employees Gelteq Limited within the market segment - Specialized pharma
Gelteq Limited specializes in developing innovative drug delivery systems, such as gels. This chart shows the percentage of chemists, pharmacologists, and technologists the company attracts in this niche pharmaceutical field. It reflects its concentration of unique scientific expertise necessary for the creation of new and more effective drug formulations.
Number of employees in the market segment - Specialized pharma
Gelteq is a company specializing in the development and production of oral gel formulations for drug delivery. These can be an alternative to tablets and injections. This graph illustrates how innovation in pharmaceuticals occurs not only in the creation of new molecules but also in improving their delivery methods, which requires the work of chemists and technologists.
Number of employees in the market as a whole
Gelteq Limited specializes in pharmaceutical development, contributing to the economy's innovative cluster. This chart shows the total number of employees, but behind these figures lies the work of thousands of scientists at these companies. Their success in creating new drugs not only saves lives but also generates high-tech exports and jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Gelteq Limited (GELS)
Gelteq is a biotech company specializing in the development of drug delivery systems (e.g., gels). This chart represents the net intellectual capital valuation. The company's value is based on its proprietary technology platform, which can improve existing drugs. The chart shows how highly the market values this scientific potential per scientist.
%20of%20the%20company%20Gelteq%20Limited%20(GELS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Gelteq-Limited-GELS&v=1772635369479 "Chart of market capitalization per employee (in thousands of dollars) of the company Gelteq Limited (GELS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Gelteq Limited specializes in the development and production of pharmaceutical gels. This is a niche business that requires specialized knowledge. This chart shows the market premium placed on the expertise of each Gelteq employee. This industry comparison helps assess how unique and valuable their drug delivery technology is considered.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772635369496 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Gelteq Limited is an Australian company developing innovative gel drug delivery systems. This chart shows the average market value of one employee's contribution, highlighting the market's appreciation for proprietary technologies in the pharmaceutical industry.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772635369512 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Gelteq Limited (GELS)
Gelteq is an R&D company developing a new oral drug delivery technology (in gel form). The company has no commercial products. This chart shows the net loss per employee. It reflects how much the company burns through each scientist to bring its technology to regulatory approval.
%20Chart%20Gelteq%20Limited%20(GELS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Gelteq-Limited-GELS&v=1772635369539 "Company Profit Per Employee (in thousands of dollars) Chart Gelteq Limited (GELS)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Gelteq Limited specializes in the development and production of innovative gel-based drug delivery systems. This is a science-intensive business requiring a team of highly qualified chemists and pharmacists. This chart illustrates how investments in research and intellectual property shape the company's potential value, expressed as a financial return per research team member.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772635369558 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Gelteq (GELS) — (Little info, micro-cap). A company developing a patented drug delivery technology in the form of oral gels as an alternative to tablets. This is an R&D business. This chart shows the average profitability per employee across the market. For GELS (which is not yet profitable), this is a benchmark: in biotech, IP allows for many times higher than this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772635369582 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Gelteq Limited (GELS)
Gelteq is a company developing new drug delivery systems, such as gels. For a specialized pharmaceutical company, this graph is a sign of the future. It reflects the potential for its innovative technologies to be licensed or commercialized, leading to increased revenue per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Gelteq-Limited-GELS&v=1772635369606 "Sales chart per company employee Gelteq Limited (GELS)")
Sales per employee in the market segment - Specialized pharma
Gelteq develops and manufactures edible gel delivery systems for nutraceuticals and pharmaceuticals. This is a niche technology. This graph shows the average revenue per employee in this segment. It helps evaluate how effectively the Gelteq team (scientists, production) is commercializing its innovative delivery system compared to competitors.
Sales per employee for the market as a whole
Gelteq — *The GELS ticker data is unclear; this may be a post-merger company. Based on the "Specialized Pharma" category*, this is a pharmaceutical company, possibly in the commercialization stage. This chart shows how effectively their commercial team (sales, marketing) converts R&D into revenue from niche drug sales.
Short shares by company, segment and market as a whole
Shares shorted by company Gelteq Limited (GELS)
Gelteq is a company developing an oral drug delivery platform in gel form (Gelteq). It's a very early-stage biotech "micro-cap." This chart shows that investors don't believe in this technology. The bears are betting that the company lacks compelling data and will burn through all of its investors' capital without creating a product.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Gelteq-Limited-GELS&v=1772635369726 "Short Shares Chart for the Company Gelteq Limited (GELS)")
Shares shorted by market segment - Specialized pharma
Gelteq Limited specializes in the development and production of oral gel-based drug delivery systems (e.g., chewable lozenges) for the pharmaceutical industry. This indicator reflects the overall volume of short positions in the pharmaceutical sector. An increase in short positions here may indicate that investors perceive risks (e.g., pricing pressure) for the entire industry.
Shares shorted by the overall market
Gelteq is a company developing gel-based drug delivery (EDV) technology. It's an early-stage biotech. This chart reflects the overall market pessimism. For investors, this is a risky R&D bet. In times of fear, the market isn't willing to fund the development of a "platform"; it wants to see a finished product.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Gelteq Limited (GELS)
This chart for Gelteq is a speculative barometer for a new drug delivery technology. The company is developing edible gel matrices (EDGEL) for drug delivery. "Overheating" (above 70) occurs on announcements of partnerships with pharmaceutical companies or positive preclinical data. This is a very early stage, and the risk of failure keeps the stock "oversold."
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Gelteq-Limited-GELS&v=1772635369842 "RSI 14 indicator chart for the company's stock Gelteq Limited (GELS)")
RSI 14 Market Segment - Specialized pharma
Gelteq (GELS) is a biotech company and a drug delivery company. Their specialty is oral delivery of complex drugs (such as semaglutide, a GLP-1 drug) in a gel. The Specialized Pharma (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether GELS's growth is due to their R&D, or if the entire biotech sector is overheated.
RSI 14 for the overall market
Gelteq (GELS) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GELS (Gelteq Limited)
Gelteq is an Australian biotech company developing a polymeric drug delivery platform (e.g., in gel form) for the treatment of skin and other diseases. This chart shows the average analyst forecast, representing their collective speculative bet on the success of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GELS-Gelteq-Limited&v=1772635369951 "A chart showing analyst consensus forecasts for the expected stock price. GELS (Gelteq Limited)")
The difference between the consensus estimate and the actual stock price GELS (Gelteq Limited)
Gelteq is an Australian biotech company developing an innovative platform (gels) for the oral delivery of drugs that are typically difficult to absorb. This chart shows the upside and downside potential analysts see for the stock. It measures the gap between the price and forecast, reflecting their confidence in the technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GELS-Gelteq-Limited&v=1772635369998 "A chart showing the difference between the consensus forecast and the actual stock price. GELS (Gelteq Limited)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Gelteq is an R&D company developing a new platform (Gelteq) for delivering medications in gel form, replacing tablets. It's betting on technology. This chart shows analysts' overall expectations for the entire specialty pharmaceutical sector. It reflects whether experts believe there will be demand for new drug delivery methods.
Analysts' consensus forecast for the overall market share price
Gelteq is an Australian company developing an innovative drug delivery platform in the form of an edible gel (for patients who have difficulty swallowing pills). It's an early-stage biotech. This chart reflects the overall "risk appetite" in the market. For Gelteq, whose value is an option on the success of their platform, overall market optimism (risk appetite) is critical for funding R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Gelteq Limited
Gelteq is an R&D company focused on delivery. Their signature product is an oral (swallowable) gel capsule (GELTEQ), which they claim enables the delivery of complex drugs (biologicals, vaccines) that typically require injections. This chart is a clear indicator of faith in their R&D platform. It reflects their (very risky) path to FDA approval and their speculative potential.
AKIMA Market Segment Index - Specialized pharma
Gelteq (GELS) is an Australian pharmaceutical company specializing in the development of oral drug delivery systems. Their technology (gels and capsules) is designed to improve the absorption and bioavailability of drugs. The chart shows the average index for the segment, helping investors assess how this platform company compares to the pharmaceutical industry average.
The AKIM Index for the overall market
Gelteq is an Australian company that has developed a gel-based delivery technology for nutrients and medications (for humans and animals). This chart, which reflects the market average, provides context. It helps assess how this innovative delivery platform compares to overall macroeconomic trends and consumer interest.
